Service of Oral and Maxillofacial Surgery, HM Nens, HM Hospitales, 08009 Barcelona, Spain.
Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Universitat Internacional de Catalunya, 08195 Sant Cugat del Vallès, Barcelona, Spain.
Benef Microbes. 2020 Nov 15;11(7):631-639. doi: 10.3920/BM2020.0090. Epub 2020 Oct 30.
The aim of this study was to investigate the effect of a probiotic in preventing infections after third molar surgery. Thirty-eight patients were consecutively enrolled to a double-blind randomised placebo-controlled trial. Patients were asked to take one tablet two times a day containing a mixture of CECT7480 (KABP-052) and CECT7481 (KABP-051) or placebo for the first post-intervention week. The primary outcome was the postoperative infection rate. Secondary outcomes included swelling, eating difficulties and postoperative pain recorded by the patient using a visual analogue scale (VAS) during the first postoperative week. No statistically significant difference in the infection rate between the groups was found; with only three cases of infections reported (one in the probiotic group and two in the placebo group) on the first week. Compared to placebo, treatment with the probiotic showed a significantly higher reduction in pain and eating difficulties scores at 5, 6 and 7 days post-surgery. Swelling values were not significantly different between the groups at any time point. The findings of this pilot study justify a larger study to clarify the possible role of these bacterial strains on the post-operative pain management following third molar surgery.
本研究旨在探讨益生菌在预防第三磨牙手术后感染中的作用。38 名患者连续纳入一项双盲随机安慰剂对照试验。患者被要求在术后第一周内每天服用两次含有 CECT7480（KABP-052）和 CECT7481（KABP-051）混合物的一片片剂或安慰剂。主要结局是术后感染率。次要结局包括肿胀、进食困难和术后疼痛，患者在术后第一周使用视觉模拟量表（VAS）进行记录。结果显示，两组间的感染率无统计学差异；仅在术后第一周报告了三例感染（益生菌组一例，安慰剂组两例）。与安慰剂相比，益生菌治疗在术后 5、6 和 7 天时疼痛和进食困难评分显著降低。两组在任何时间点的肿胀值均无显著差异。这项初步研究的结果证明，需要进行更大规模的研究来阐明这些细菌菌株在后第三磨牙手术后疼痛管理中的可能作用。
